[THE INVESTOR] On Oct. 13, Whanin Pharmaceuticals (016580) declined 1.61% to 15,300 won (US$ 13.47). It had declined 2.87% through the past month. Standard deviation, which indicates risk, records 1.7% on the same period over one month.

Compared with its close competitors within the same industry, KOSPI, since the monthly volatility of Whanin Pharmaceuticals was at a low level, the earnings rate over one month was also relatively lower than that of its peer group. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -1.6%. As bearish stock price trend, the return-on-risk was poor its peer group. However, the return-on-risk is much better than the industrial mean, -3.3, and thus the industrial comparison performance was positive.

Comparing industry to the market, the KOSPI industry including Whanin Pharmaceuticals records higher volatility but lower earning rate than Medical Supplies. Even though the earning rate of the industry is negative, the industry was more satisfactory than the market.

From Oct. 05, foreigners have been continuously selling Whanin Pharmaceuticals during the past 6 trading days. As a shareholding sum by investor group for the past 4 weeks, institutions have bought 40,561 shares in spite of lowered the position recently. However, during the same period, foreigners have sold 30,621 shares and individuals have sold 9,940 shares in a lessening selling trend.

Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.